Kaken Pharmaceutical Co., Ltd. (TYO:4521)

Market Cap	150.72B +2.5%
Revenue (ttm)	88.16B -6.9%
Net Income	10.31B -17.3%
EPS	272.32 -16.5%
Shares Out	37.87M
PE Ratio	14.62
Forward PE	34.28
Dividend	190.00 (4.75%)
Ex-Dividend Date	Sep 29, 2026

Volume	124,200
Open	3,980.00
Previous Close	3,980.00
Day's Range	3,970.00 - 4,015.00
52-Week Range	3,540.00 - 4,445.00
Beta	0.13
Analysts	Hold
Price Target	4,575.00 (+14.81%)
Earnings Date	Aug 7, 2026

About Kaken Pharmaceutical

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surger...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1917
• Employees: 1,114
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4521

Financial Performance

In fiscal year 2026, Kaken Pharmaceutical's revenue was 76.87 billion, a decrease of -18.25% compared to the previous year's 94.04 billion. Earnings were 2.14 billion, a decrease of -84.63%.

Analyst Summary

According to 4 analysts, the average rating for 4521 stock is "Hold." The 12-month stock price target is ¥4,575, which is an increase of 14.81% from the latest price.

Price Target

¥4,575

(14.81% upside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 25, 2026

Data Sources Report a data error